Objective：To systematically evaluate the efficacy and safety of everolimus-eluting stents（EES） versus sirolimus-eluting stents（SES） in the treatment of patients with coronary artery disease undergoing percutaneous coronary intervention. Methods：Databas－es such as PubMed，EMbase，Cochrane Library and CNKI were searched to collect all the randomized controlled trials（RCTs） of EES versus SES in patients with coronary artery disease from 2000 to 2012. After the data extraction and methodological quality evaluation，Meta analysis was conducted with RevMan 5.0 software. Results：A total of 10 RCTs were included. Among 12 937 patients involved，6 378 were in EES group while the other 6 559 were in SES group. Results of Meta analysis showed that EES was superior to SES in reducing definite stent thrombosis rates（OR=0.47，95%CI=0.26 to 0.85，P=0.01）. In contrast，there were no significant differences between EES and SES in target-lesion revascularization rates（OR=0.85，95%CI=0.70 to 1.03，P=0.11），target-vessel revasculariza－tion rates（OR=0.92，95%CI=0.77 to 1.09，P=0.33），cardiac death rates（OR=0.91，95%CI=0.69 to 1.20，P=0.52），incidences of major adverse cardiac event（OR=0.89，95%CI=0.78 to 1.02，P=0.09） and recurrence rates of myocardial infarction（OR=0.95，95%CI=0.75 to 1.19，P=0.63）. Conclusions：EES is more effective than SES in reducing the rate of definite stent thrombosis.